{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:49:06Z","timestamp":1760100546376},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s00404-012-2589-7","type":"journal-article","created":{"date-parts":[[2012,11,7]],"date-time":"2012-11-07T05:33:20Z","timestamp":1352266400000},"page":"563-570","source":"Crossref","is-referenced-by-count":10,"title":["MRP2 (ABCC2, cMOAT) expression in nuclear envelope of primary fallopian tube cancer cells is a new unfavorable prognostic factor"],"prefix":"10.1007","volume":"287","author":[{"given":"Agnieszka","family":"Halon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Materna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Donizy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafal","family":"Matkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Rabczynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Lage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Surowiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,8]]},"reference":[{"key":"2589_CR1","unstructured":"Reports based on data of the National Cancer Registry in Poland: http:\/\/85.128.14.124\/krn\/english\/index.asp"},{"key":"2589_CR2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ygyno.2007.09.018","volume":"107","author":"SL Stewart","year":"2007","unstructured":"Stewart SL, Wike JM, Foster SL, Michaud F (2007) The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol 107:392\u2013397","journal-title":"Gynecol Oncol"},{"key":"2589_CR3","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1002\/cncr.23957","volume":"113","author":"SL Wethington","year":"2008","unstructured":"Wethington SL, Herzog TJ, Seshan VE et al (2008) Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. Cancer 113:3298\u20133306","journal-title":"Cancer"},{"key":"2589_CR4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0002-9378(50)90341-3","volume":"59","author":"CY Hu","year":"1950","unstructured":"Hu CY, Taymour ML, Hertig AT (1950) Primary carcinoma of the fallopian tube. Am J Obstet Gynaecol 59:58\u201367","journal-title":"Am J Obstet Gynaecol"},{"key":"2589_CR5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0039-6109(16)41439-8","volume":"58","author":"A Sedlis","year":"1978","unstructured":"Sedlis A (1978) Carcinoma of the fallopian tube. Surg Clin North Am 58:121\u2013129","journal-title":"Surg Clin North Am"},{"key":"2589_CR6","first-page":"693","volume":"27","author":"P Ng","year":"1998","unstructured":"Ng P, Lawton F (1998) Fallopian tube carcinoma\u2013a review. Ann Acad Med Singapore 27:693\u2013697","journal-title":"Ann Acad Med Singapore"},{"key":"2589_CR7","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1073\/pnas.1017300108","volume":"108","author":"AM Karst","year":"2011","unstructured":"Karst AM, Levanon K, Drapkin R (2011) Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci USA 108:7547\u20137552","journal-title":"Proc Natl Acad Sci USA"},{"key":"2589_CR8","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1200\/JCO.2008.18.1107","volume":"26","author":"K Levanon","year":"2008","unstructured":"Levanon K, Crum C, Drapkin R (2008) New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26:5284\u20135293","journal-title":"J Clin Oncol"},{"key":"2589_CR9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1006\/gyno.1998.5267","volume":"72","author":"I Alvarado-Cabrero","year":"1999","unstructured":"Alvarado-Cabrero I, Young RH, Vamvakas EC et al (1999) Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol 72:367\u2013379","journal-title":"Gynecol Oncol"},{"key":"2589_CR10","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1002\/1097-0142(20001115)89:10<2076::AID-CNCR7>3.0.CO;2-V","volume":"89","author":"M Baekelandt","year":"2000","unstructured":"Baekelandt M, Nesbakken AJ, Kristensen GB et al (2000) Carcinoma of the fallopian tube. Clinicopathologic study of 151 patients treated at the Norwegian Radium Hospital. Cancer 89:2076\u20132084","journal-title":"Cancer"},{"key":"2589_CR11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00006254-199405000-00026","volume":"49","author":"AJ Nordin","year":"1994","unstructured":"Nordin AJ (1994) Primary carcinoma of the fallopian tube: a 20-year literature review. Obstet Gynaecol Surv 49:349\u2013361","journal-title":"Obstet Gynaecol Surv"},{"key":"2589_CR12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1525-1438.1994.04060395.x","volume":"4","author":"AC Hellstr\u00f6m","year":"1994","unstructured":"Hellstr\u00f6m AC, Silfversw\u00e4rd C, Nilsson B et al (1994) Carcinoma of the fallopian tube. A clinical and histopathologic review. The Radiumhemmet series. Int J Gynecol Cancer 4:395\u2013400","journal-title":"Int J Gynecol Cancer"},{"key":"2589_CR13","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0959-8049(98)00214-7","volume":"34","author":"AC Rosen","year":"1998","unstructured":"Rosen AC, Ausch M, Hafner E et al (1998) A 15-year overview of management and prognosis in fallopian tube carcinoma. Austrian Cooperative Study Group for Fallopian Tube Carcinoma. Eur J Cancer 34:1725\u20131729","journal-title":"Eur J Cancer"},{"key":"2589_CR14","first-page":"285","volume":"49","author":"J Rabczy\u0144ski","year":"1998","unstructured":"Rabczy\u0144ski J, Zi\u00f3\u0142kowski P, Kochman A et al (1998) Primary fallopian tube carcinoma. Histopathology of 46 cases. Pol J Pathol 49:285\u2013292","journal-title":"Pol J Pathol"},{"key":"2589_CR15","first-page":"389","volume":"30","author":"CA Papadimitriou","year":"2009","unstructured":"Papadimitriou CA, Markaki S, Lianos E et al (2009) Clinicopathological features of primary fallopian tube carcinoma: a single institution experience. Eur J Gynaecol Oncol 30:389\u2013395","journal-title":"Eur J Gynaecol Oncol"},{"key":"2589_CR16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ygyno.2009.06.025","volume":"115","author":"D Pectasides","year":"2009","unstructured":"Pectasides D, Pectasides E, Papaxoinis G et al (2009) Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients. Gynecol Oncol 115:97\u2013101","journal-title":"Gynecol Oncol"},{"key":"2589_CR17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/01443610701811894","volume":"28","author":"A Liapis","year":"2008","unstructured":"Liapis A, Bakalianou K, Mpotsa E et al (2008) Fallopian tube malignancies: a retrospective clinical pathological study of 17 cases. J Obstet Gynaecol 28:93\u201395","journal-title":"J Obstet Gynaecol"},{"key":"2589_CR18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1006\/gyno.2000.5740","volume":"77","author":"PG Rose","year":"2000","unstructured":"Rose PG, Shrigley R, Wiesner GL (2000) Germline BRCA2 mutation in patient with primary fallopian tube carcinoma: a case report. Gynecol Oncol 77:319\u2013320","journal-title":"Gynecol Oncol"},{"key":"2589_CR19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1006\/gyno.2000.6095","volume":"80","author":"S Aziz","year":"2001","unstructured":"Aziz S, Kuperstein G, Rosen B et al (2001) A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 80:341\u2013345","journal-title":"Gynecol Oncol"},{"key":"2589_CR20","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1634\/theoncologist.11-8-902","volume":"11","author":"D Pectasides","year":"2006","unstructured":"Pectasides D, Pectasides E, Economopoulos T (2006) Fallopian tube carcinoma: a review. Oncologist 11:902\u2013912","journal-title":"Oncologist"},{"key":"2589_CR21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1006\/gyno.2002.6743","volume":"86","author":"C Kosary","year":"2002","unstructured":"Kosary C, Trimble EL (2002) Treatment and survival for women with fallopian tube carcinoma: a population-based study. Gynecol Oncol 86:190\u2013191","journal-title":"Gynecol Oncol"},{"key":"2589_CR22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1006\/gyno.2001.6134","volume":"81","author":"A Gadducci","year":"2001","unstructured":"Gadducci A, Landoni F, Sartori E et al (2001) Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study. Gynecol Oncol 81:150\u2013159","journal-title":"Gynecol Oncol"},{"key":"2589_CR23","first-page":"757","volume":"71","author":"WA Peters","year":"1988","unstructured":"Peters WA, Andersen WA, Hopkins MP (1988) Prognostic features of carcinoma of the fallopian tube. Obstet Gynecol 71:757\u2013762","journal-title":"Obstet Gynecol"},{"key":"2589_CR24","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1038\/sj.onc.1206953","volume":"22","author":"GD Kruh","year":"2003","unstructured":"Kruh GD, Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22:7537\u20137552","journal-title":"Oncogene"},{"key":"2589_CR25","first-page":"4124","volume":"56","author":"K Taniguchi","year":"1996","unstructured":"Taniguchi K, Wada M, Kohno K et al (1996) A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56:4124\u20134129","journal-title":"Cancer Res"},{"key":"2589_CR26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1523-1747.2003.12313.x","volume":"121","author":"B Liedert","year":"2003","unstructured":"Liedert B, Materna V, Schadendorf D et al (2003) Overexpression of cMOAT (MRP2\/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 121:172\u2013176","journal-title":"J Invest Dermatol"},{"key":"2589_CR27","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1158\/1078-0432.CCR-06-0564","volume":"12","author":"P Surowiak","year":"2006","unstructured":"Surowiak P, Materna V, Kaplenko I et al (2006) ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res 12:7149\u20137158","journal-title":"Clin Cancer Res"},{"key":"2589_CR28","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/hmg\/7.2.203","volume":"7","author":"M Wada","year":"1998","unstructured":"Wada M, Toh S, Taniguchi K et al (1998) Mutations in the canalicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II\/Dubin-Johnson syndrome. Hum Mol Genet 7:203\u2013207","journal-title":"Hum Mol Genet"},{"key":"2589_CR29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bbrc.2006.07.022","volume":"348","author":"V Materna","year":"2006","unstructured":"Materna V, Stege A, Surowiak P et al (2006) RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Commun 348:153\u2013157","journal-title":"Biochem Biophys Res Commun"},{"key":"2589_CR30","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.ymthe.2004.11.016","volume":"11","author":"P Kowalski","year":"2005","unstructured":"Kowalski P, Surowiak P, Lage H (2005) Reversal of drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1\/P-gp, MRP2, and BCRP. Mol Ther 11:1393\u20131398","journal-title":"Mol Ther"},{"key":"2589_CR31","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138\u2013140","journal-title":"Pathologe"},{"key":"2589_CR32","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.bjc.6606071","volume":"104","author":"M Yamasaki","year":"2011","unstructured":"Yamasaki M, Makino T, Masuzawa T et al (2011) Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer 104:707\u2013713","journal-title":"Br J Cancer"},{"key":"2589_CR33","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.5858\/2006-130-1014-IOMPAC","volume":"130","author":"RM Ruggeri","year":"2006","unstructured":"Ruggeri RM, Sciacchitano S, Vitarelli E et al (2006) Immunoexpression of multidrug-resistance protein 2 and cyclooxygenase 2 in medullary thyroid carcinomas. Arch Pathol Lab Med 130:1014\u20131019","journal-title":"Arch Pathol Lab Med"},{"key":"2589_CR34","first-page":"1187","volume":"33","author":"B Noma","year":"2008","unstructured":"Noma B, Sasaki T, Fujimoto Y et al (2008) Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Int J Oncol 33:1187\u20131194","journal-title":"Int J Oncol"},{"key":"2589_CR35","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1002\/ijc.24254","volume":"124","author":"GB Broek van den","year":"2009","unstructured":"van den Broek GB, Wildeman M, Rasch CR et al (2009) Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer 124:2643\u20132650","journal-title":"Int J Cancer"},{"key":"2589_CR36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2008.10.008","volume":"65","author":"YH Kim","year":"2009","unstructured":"Kim YH, Ishii G, Goto K et al (2009) Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 65:105\u2013111","journal-title":"Lung Cancer"},{"key":"2589_CR37","first-page":"4351","volume":"27","author":"R Ushijima","year":"2007","unstructured":"Ushijima R, Takayama K, Izumi M et al (2007) Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer. Anticancer Res 27:4351\u20134358","journal-title":"Anticancer Res"},{"key":"2589_CR38","first-page":"965","volume":"23","author":"PV Korita","year":"2010","unstructured":"Korita PV, Wakai T, Shirai Y et al (2010) Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep 23:965\u2013972","journal-title":"Oncol Rep"},{"key":"2589_CR39","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2362.2007.01916.x","volume":"38","author":"S Rau","year":"2008","unstructured":"Rau S, Autschbach F, Riedel HD et al (2008) Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas. Eur J Clin Invest 38:134\u2013142","journal-title":"Eur J Clin Invest"},{"key":"2589_CR40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1046\/j.1365-2559.2002.01403.x","volume":"41","author":"GE Sandusky","year":"2002","unstructured":"Sandusky GE, Mintze KS, Pratt SE et al (2002) Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 41:65\u201374","journal-title":"Histopathology"},{"key":"2589_CR41","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/sj.bjc.6605185","volume":"101","author":"H Chen","year":"2009","unstructured":"Chen H, Hao J, Wang L (2009) Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDRI, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101:432\u2013440","journal-title":"Br J Cancer"},{"key":"2589_CR42","first-page":"3767","volume":"8","author":"Y Ohishi","year":"2002","unstructured":"Ohishi Y, Oda Y, Uchiumi T et al (2002) ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res 8:3767\u20133775","journal-title":"Clin Cancer Res"},{"key":"2589_CR43","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2004.03.035","volume":"94","author":"V Materna","year":"2004","unstructured":"Materna V, Pleger J, Hoffmann U et al (2004) RNA expression of MDR1\/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 94:152\u2013160","journal-title":"Gynecol Oncol"},{"key":"2589_CR44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2005.08.046","volume":"100","author":"AD Guminski","year":"2006","unstructured":"Guminski AD, Balleine RL, Chiew YE et al (2006) MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol Oncol 100:239\u2013246","journal-title":"Gynecol Oncol"},{"key":"2589_CR45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00404-008-0690-8","volume":"279","author":"JJ Ma","year":"2009","unstructured":"Ma JJ, Chen BL, Xin XY (2009) Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene. Arch Gynecol Obstet 279:149\u2013157","journal-title":"Arch Gynecol Obstet"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-012-2589-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T23:47:02Z","timestamp":1643586422000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-012-2589-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,8]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["2589"],"URL":"https:\/\/doi.org\/10.1007\/s00404-012-2589-7","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,8]]}}}